Sign In
Buy CNTB
$2.23
+0.0800 (+3.72%)
At Close: Jun 03, 2026
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
12:05am, Friday, 22'nd May 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
04:05pm, Tuesday, 12'th May 2026
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transfo
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
09:00am, Tuesday, 12'th May 2026
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma: New Market Opportunity In The Emergency Setting
10:08am, Wednesday, 29'th Apr 2026
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
04:05pm, Tuesday, 31'st Mar 2026
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-b
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Connect Biopharma Announces $20.2 Million Private Placement Financing
07:02am, Monday, 30'th Mar 2026
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (�
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
07:01am, Monday, 30'th Mar 2026
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients –
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experienci
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:26am, Wednesday, 11'th Mar 2026
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are presently coverin
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on tran
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
09:00am, Tuesday, 03'rd Mar 2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compa
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference
05:04am, Monday, 02'nd Mar 2026
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it
BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB
04:22am, Monday, 23'rd Feb 2026
BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB) by 30.4% during the third quarter, according to its most recent 13F filing with the Securiti
